MOESM4 of Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL Virginie Nägele Andrea Kratzer Gerhard Zugmaier Chris Holland Youssef Hijazi Max Topp Nicola Gökbuget Patrick Baeuerle Peter Kufer Andreas Wolf Matthias Klinger 10.6084/m9.figshare.c.3783488_D4.v1 https://springernature.figshare.com/articles/journal_contribution/MOESM4_of_Changes_in_clinical_laboratory_parameters_and_pharmacodynamic_markers_in_response_to_blinatumomab_treatment_of_patients_with_relapsed_refractory_ALL/5024294 Additional file 4. Available patient numbers (N) for analysis of distribution profiles of CD8+ and CD4+ T cells and subsets in Fig. 4. 2017-05-18 05:00:00 Acute lymphoblastic leukemia Blinatumomab Bispecific BiTE® CD19 Liver enzymes Pharmacodynamics